Fundraising FoxO2h Ventures — Full Portfolio
16 tracked investments · listed companies and verified rows first
Helus Pharma is a clinical-stage biopharmaceutical company developing small-molecule therapies for psychiatric and CNS conditions such as depression, anxiety, schizophrenia, and bipolar disorder.
BiotechDigital HealthHealthtechMental HealthToronto, CA
Eric So(Co-Founder, Executive Chairman)inJohn Kanakis(Co-Founder)inPaul Glavine(Co-Founder and Chief Growth Officer)inGabriel Fahel(Executive Officer)Douglas Drysdale(Executive Officer)Jacqueline Poriadjian(Executive Officer)
Co-investorsInnovating CapitalJLSNoetic
Exonate is a biotechnology company developing treatments for retinal vascular diseases, with a lead asset (EXN407) intended as a topical therapy for diabetic retinopathy and diabetic macular oedema.
BiotechDigital HealthHealthtechMedical Devices
Olav Hellebø(Chief Executive Officer)in
Co-investorsWellcome TrustWren CapitalCambridge Angels groupEMV CapitalMartlet CapitalStoic VC+1 more
Metrion Biosciences provides ion channel screening and drug discovery services for pharmaceutical and biotech companies.
BiotechDeep TechMedical DevicesCambridge, GB
Marc Rogers(Founding Director)inJohn Ford(Founding Director)inKeith McCullagh(Founding Director)inLee Patterson(Chief Executive Officer)in
Co-investorsGresham House VenturesMaven Capital Partners
Stratosvir develops engineered viral immunotherapy treatments for advanced cancers, including prostate cancer, using modified viruses to activate the body's immune system against tumors.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesStevenage, GB
Dr Chris Ullman(CEO)inAntonio Postigo(CSO)in
BoardPriya Mande(Chairman)in
Co-investorsDeep Science Ventures
Atelerix develops hypothermic hydrogel encapsulation technology that stabilises and preserves fresh cells, tissues, and blood at room temperature, eliminating the need for cryopreservation and cold-chain logistics.
BiotechMedical DevicesNew Materials
Steve Swioklo(Founder)in
Co-investorsCambridge Angels groupFuture Planet CapitalOxford Technology ManagementUK Innovation & Science Seed Fund
Enedra analyzes tumor evolution patterns by decoding convergent genomic signatures from cancer genomic data.
AI & Machine LearningBiotechMedical Devices
Co-investorsDeep Science VenturesKU Leuven Research & Development
The Financial Ombudsman Service is a free, statutory body set up by UK Parliament in 2001 to investigate and resolve complaints between consumers and financial businesses such as banks, insurers, and pension and investment providers.
FintechGovTechLegalTech
Co-investorsDeepbridge CapitalForce Over Mass CapitalFuel VenturesOxfordQVenturesSeneca Partners+1 more
Five Alarm Bio develops pharmaceutical compounds targeting a novel aging mechanism to prevent and treat age-related chronic diseases.
BiotechLongevity
William Bains(Founding scientist)in
Co-investorsCambridge Angels groupSyndicateRoom
BiotechDundee, Scotland
Timothy Jason Sparey(Executive Officer)Antoine Boulanger(Executive Officer)Francisca Peixoto(Executive Officer)Christopher Andrew Woodland(Executive Officer, Director)
BoardMary Canning(Executive Officer)
Co-investorsEpidarex Capital
Pencil is an AI operating system for marketing that aggregates multiple AI models (from OpenAI, Google, Adobe, Runway, and Bria) into one orchestration layer with enterprise governance controls.
AI & Machine LearningEnterprise SoftwareMarketing TechSingapore, SG
Will Hanschell(CEO)inSumukh Avadhani(CTO)in
Co-investorsBrandtech VenturesEntrepreneur FirstWavemaker PartnersArtesianCatapult VenturesMartlet Capital+6 more
PharmEnable applies AI to small molecule drug discovery, focusing on challenging and data-sparse biological targets that traditional methods struggle to address.
AI & Machine LearningBiotechDeep Tech
Hannah Sore(Founder)in
Co-investorsCambridge Angels groupMartlet CapitalMC Healthcare VenturesDiamond Edge VenturesParkwalk AdvisorsWren Capital
PhoreMost is a biotechnology company developing small molecule drugs and targeted protein degradation therapeutics for cancers with high unmet clinical need, with a lead program (PMC-001) for primary and metastatic brain cancers in Phase 1/2a clinical evaluation.
BiotechMedical DevicesCambridge, GB
Co-investorsAmadeus Capital PartnersAstellas Venture Management LLCCambridge Angels groupUniversity of Cambridge EnterpriseAmadeus Capital SAParkwalk Advisors
Helus Pharma is a clinical-stage pharmaceutical company developing novel serotonergic agonists—synthetic molecules that activate serotonin pathways—as next-generation mental health therapies.
BiotechHealthtechMental HealthLondon
Eric So(Co-Founder, Executive Chairman)Carol Routledge(Executive Officer)George Tziras(Director)Khalid Howladar(Director)Marie Claire Layzell(Executive Officer, Director)Peter Rands(Executive Officer, Director)
Spirea develops a multivalent ADC linker technology called ELIVATE that expands the range of usable payloads for antibody-drug conjugates, aiming to enable next-generation ADCs for oncology, inflammation, and autoimmune diseases.
BiotechDeep TechHealthtech
Myriam Ouberai(Founder)inBo Rode Hansen(Executive Director)in
Co-investorsCambridge Angels groupStart CodonACF InvestorsR42 Group
Stemnovate provides an integrated platform combining multiomics data, cell reprogramming technology, and mechanistic functional studies to accelerate drug discovery and clinical translation for rare diseases, neurodegenerative conditions, and other therapeutic areas across human and animal health.
AI & Machine LearningBiotechDeep Tech
Co-investorsCambridge Angels group
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.